William W Roberts1. 1. Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
PURPOSE OF REVIEW: The aim of this article is to outline the initial development of histotripsy, a noninvasive image-guided focused ultrasound technology that mechanically homogenizes targeted tissues and to describe the results of preclinical translational research directed toward urologic applications. RECENT FINDINGS: Histotripsy tissue ablation is based on initiation and control of acoustic cavitation at a target point within the body. This unique mechanical mechanism of action is distinct when compared with conventional thermal ablative modalities. Features of histotripsy (nonthermal, noninvasive, high precision, real-time monitoring/feedback, and tissue liquefaction) have prompted assessment of this technology as a potential ablative therapy for a number of organs and disease processes. SUMMARY: Ongoing research efforts to apply histotripsy to preclinical models of benign prostatic hyperplasia, prostate cancer, renal masses, and renal calculi have resulted in enhanced understanding of cavitation bioeffects, refinement of treatment systems, strategies to enhance treatment efficiency, and initiation of a pilot human clinical trial to assess the safety of histotripsy for benign prostatic hyperplasia therapy.
PURPOSE OF REVIEW: The aim of this article is to outline the initial development of histotripsy, a noninvasive image-guided focused ultrasound technology that mechanically homogenizes targeted tissues and to describe the results of preclinical translational research directed toward urologic applications. RECENT FINDINGS: Histotripsy tissue ablation is based on initiation and control of acoustic cavitation at a target point within the body. This unique mechanical mechanism of action is distinct when compared with conventional thermal ablative modalities. Features of histotripsy (nonthermal, noninvasive, high precision, real-time monitoring/feedback, and tissue liquefaction) have prompted assessment of this technology as a potential ablative therapy for a number of organs and disease processes. SUMMARY: Ongoing research efforts to apply histotripsy to preclinical models of benign prostatic hyperplasia, prostate cancer, renal masses, and renal calculi have resulted in enhanced understanding of cavitation bioeffects, refinement of treatment systems, strategies to enhance treatment efficiency, and initiation of a pilot human clinical trial to assess the safety of histotripsy for benign prostatic hyperplasia therapy.
Authors: Simone Park; Adam D Maxwell; Gabe E Owens; Hitinder S Gurm; Charles A Cain; Zhen Xu Journal: Ultrasound Med Biol Date: 2013-02-13 Impact factor: 2.998
Authors: George R Schade; Jill Keller; Kim Ives; Xu Cheng; Thomas J Rosol; Evan Keller; William W Roberts Journal: J Urol Date: 2012-09-20 Impact factor: 7.450
Authors: Frank Winterroth; Zhen Xu; Tzu-Yin Wang; J Erby Wilkinson; J Brian Fowlkes; William W Roberts; Charles A Cain Journal: Ultrasound Med Biol Date: 2011-01 Impact factor: 2.998
Authors: Yohan Kim; Carlen G Fifer; Sarah K Gelehrter; Gabe E Owens; Deborah R Berman; Eli Vlaisavljevich; Steven P Allen; Maria F Ladino-Torres; Zhen Xu Journal: Ultrasound Med Biol Date: 2013-02-27 Impact factor: 2.998
Authors: Julianna C Simon; Oleg A Sapozhnikov; Vera A Khokhlova; Yak-Nam Wang; Lawrence A Crum; Michael R Bailey Journal: Phys Med Biol Date: 2012-11-16 Impact factor: 3.609
Authors: Jill M Keller; George R Schade; Kimberly Ives; Xu Cheng; Thomas J Rosol; Morand Piert; Javed Siddiqui; William W Roberts; Evan T Keller Journal: Prostate Date: 2013-01-17 Impact factor: 4.104
Authors: Alexander P Duryea; William W Roberts; Charles A Cain; Timothy L Hall Journal: IEEE Trans Ultrason Ferroelectr Freq Control Date: 2013-02 Impact factor: 2.725
Authors: Emily A Knott; Katherine C Longo; Eli Vlaisavljevich; Xaiofei Zhang; John F Swietlik; Zhen Xu; Allison C Rodgers; Annie M Zlevor; Paul F Laeseke; Timothy L Hall; Fred T Lee; Timothy J Ziemlewicz Journal: Cardiovasc Intervent Radiol Date: 2021-07-09 Impact factor: 2.740
Authors: Ying Meng; Christopher B Pople; Dan Budiansky; Daniel Li; Suganth Suppiah; Mary Jane Lim-Fat; James Perry; Arjun Sahgal; Nir Lipsman Journal: J Neurooncol Date: 2021-10-18 Impact factor: 4.130
Authors: Brittanie Partridge; John H Rossmeisl; Alexandra M Kaloss; Erwin Kristobal Gudenschwager Basso; Michelle H Theus Journal: J Neurosci Methods Date: 2020-02-14 Impact factor: 2.390
Authors: Gregory J Anthony; Viktor Bollen; Samuel Hendley; Tatjana Antic; Steffen Sammet; Kenneth B Bader Journal: Phys Med Biol Date: 2019-05-02 Impact factor: 4.174
Authors: Avinash Eranki; Navid Farr; Ari Partanen; Karun V Sharma; Hong Chen; Christopher T Rossi; Satya V V N Kothapalli; Matthew Oetgen; AeRang Kim; Ayele H Negussie; David Woods; Bradford J Wood; Peter C W Kim; Pavel S Yarmolenko Journal: PLoS One Date: 2017-03-16 Impact factor: 3.240